Korean J Gastroenterol.  2015 Oct;66(4):202-208. 10.4166/kjg.2015.66.4.202.

Uric Acid Is a Risk Indicator for Metabolic Syndrome-related Colorectal Adenoma: Results in a Korean Population Receiving Screening Colonoscopy

• Kim HJ
• Kim JE
• Jung JH
• Kim ER
• Hong SN
• Chang DK
• Son HJ
• Rhee PL
• Kim JJ
• Kim YH

• KMID: 2373342
• DOI: http://doi.org/10.4166/kjg.2015.66.4.202

Abstract

BACKGROUND/AIMS
An association between serum uric acid and cancer risk has been noted over the past few decades. There is ongoing debate about whether hyperuricemia represents an independent risk factor for colorectal neoplasm. We investigated the association between serum uric acid and prevalence of colorectal adenoma considering numerous confounding factors.
METHODS
A cross-sectional study was performed with individuals who underwent a routine health check-up examination, including a screening colonoscopy and blood chemistry. The association between serum uric acid and prevalence of colorectal adenoma was estimated from the results of a logistic regression analysis.
RESULTS
Of the 1,066 participants, 402 had colorectal adenoma (37.7%). In univariate models, the prevalence of colorectal adenoma was higher in participants in the fourth quartile uric acid level, compared to those in the first quartile uric acid level (OR, 1.67; 95% CI, 1.17-2.42; p=0.004). However, no significant association was detected between serum uric acid and prevalence of colorectal adenoma in multiple logistic regression analysis. A number of metabolic syndrome components exhibited a strong association with the prevalence of colorectal adenoma in the multivariate model (OR, 3.46 for highest vs. lowest; 95% CI, 1.30-9.20; p=0.021). Moreover, serum uric acid was strongly associated with metabolic syndrome-associated variables, including waist circumference, fasting blood glucose, systolic blood pressure, diastolic blood pressure, triglyceride, and high-density lipoprotein.
CONCLUSIONS
Uric acid is not an independent risk factor for colorectal adenoma but is a risk indicator for metabolic syndrome-related colorectal adenoma.

Keyword

Colorectal neoplasms; Uric acid; Metabolic syndrome X

MeSH Terms

Adenoma/*diagnosis/epidemiology/etiology
Adult
Asian Continental Ancestry Group
Blood Glucose/analysis
Blood Pressure
Colonoscopy
Colorectal Neoplasms/*diagnosis/epidemiology/etiology
Cross-Sectional Studies
Female
Humans
Logistic Models
Male
Metabolic Syndrome X/*diagnosis
Middle Aged
Odds Ratio
Prevalence
Republic of Korea
Risk Factors
Triglycerides/blood
Uric Acid/*blood/urine
Waist Circumference
Blood Glucose
Triglycerides
Uric Acid

Reference

References

1. Fini MA, Elias A, Johnson RJ, Wright RM. Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Transl Med. 2012; 1:16.

2. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radi-cal-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A. 1981; 78:6858–6862.

3. Becker BF. Towards the physiological function of uric acid. Free Radic Biol Med. 1993; 14:615–631.

4. Strasak AM, Rapp K, Hilbe W, et al. VHM&PP Study Group. The role of serum uric acid as an antioxidant protecting against cancer: prospective study in more than 28 000 older Austrian women. Ann Oncol. 2007; 18:1893–1897.

5. Strasak AM, Rapp K, Hilbe W, et al. VHM&PP Study Group. Serum uric acid and risk of cancer mortality in a large prospective male cohort. Cancer Causes Control. 2007; 18:1021–1029.

6. Ruggiero C, Cherubini A, Lauretani F, et al. Uric acid and dementia in community-dwelling older persons. Dement Geriatr Cogn Disord. 2009; 27:382–389.

7. Ultmann JE. Hyperuricemia in disseminated neoplastic disease other than lymphomas and leukemias. Cancer. 1962; 15:122–129.

8. Pochedly C. Hyperuricemia in leukemia and lymphoma. I. Clinical findings and pathophysiology. N Y State J Med. 1973; 73:1085–1092.

9. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003; 42:474–480.

10. Nakanishi N, Okamoto M, Yoshida H, Matsuo Y, Suzuki K, Tatara K. Serum uric acid and risk for development of hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers. Eur J Epidemiol. 2003; 18:523–530.

11. Abdullah AR, Hasan HA, Raigangar VL. Analysis of the relationship of leptin, high-sensitivity C-reactive protein, adiponectin, insulin, and uric acid to metabolic syndrome in lean, overweight, and obese young females. Metab Syndr Relat Disord. 2009; 7:17–22.

12. Pladevall M, Singal B, Williams LK, et al. A single factor underlies the metabolic syndrome: a confirmatory factor analysis. Diabetes Care. 2006; 29:113–122.

13. Wang YY, Lin SY, Lai WA, Liu PH, Sheu WH. Association between adenomas of rectosigmoid colon and metabolic syndrome features in a Chinese population. J Gastroenterol Hepatol. 2005; 20:1410–1415.

14. Kim JH, Lim YJ, Kim YH, et al. Is metabolic syndrome a risk factor for colorectal adenoma? Cancer Epidemiol Biomarkers Prev. 2007; 16:1543–1546.

15. Liu CS, Hsu HS, Li CI, et al. Central obesity and atherogenic dyslipidemia in metabolic syndrome are associated with increased risk for colorectal adenoma in a Chinese population. BMC Gastroenterol. 2010; 10:51.

16. Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR. The metabolic syndrome and risk of incident colorectal cancer. Cancer. 2006; 107:28–36.

17. Stocks T, Lukanova A, Bjørge T, et al. Metabolic Syndrome Cancer Project Me-Can Group. Metabolic factors and the risk of colorectal cancer in 580,000 men and women in the metabolic syndrome and cancer project (Me-Can). Cancer. 2011; 117:2398–2407.

18. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM. American College of Gastroenterology. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol. 2009; 104:739–750.

19. Bond JH. Polyp guideline: diagnosis, treatment, and surveillance for patients with colorectal polyps. Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 2000; 95:3053–3063.

20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on Detection, Evaluation, and Treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001; 285:2486–2497.

21. Boffetta P, Nordenvall C, Nyrén O, Ye W. A prospective study of gout and cancer. Eur J Cancer Prev. 2009; 18:127–132.

22. Hiatt RA, Fireman BH. Serum uric acid unrelated to cancer incidence in humans. Cancer Res. 1988; 48:2916–2918.

23. Colangelo LA, Gapstur SM, Gann PH, Dyer AR, Liu K. Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomarkers Prev. 2002; 11:385–391.

24. Kolonel LN, Yoshizawa C, Nomura AM, Stemmermann GN. Relationship of serum uric acid to cancer occurrence in a prospective male cohort. Cancer Epidemiol Biomarkers Prev. 1994; 3:225–228.

25. Peden DB, Hohman R, Brown ME, et al. Uric acid is a major antioxidant in human nasal airway secretions. Proc Natl Acad Sci U S A. 1990; 87:7638–7642.

26. Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2006; 290:F625–F631.

27. Tang W, Hong Y, Province MA, et al. Familial clustering for features of the metabolic syndrome: the National Heart, Lung, and Blood Institute (NHLBI) Family Heart Study. Diabetes Care. 2006; 29:631–636.

28. Stellato D, Morrone LF, Di Giorgio C, Gesualdo L. Uric acid: a star-ring role in the intricate scenario of metabolic syndrome with car-dio-renal damage? Intern Emerg Med. 2012; 7:5–8.

29. Salehidoost R, Aminorroaya A, Zare M, Amini M. Is uric acid an indicator of metabolic syndrome in the first-degree relatives of patients with type 2 diabetes? J Res Med Sci. 2012; 17:1005–1010.

30. Matsuura F, Yamashita S, Nakamura T, et al. Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabolism. 1998; 47:929–933.

31. Takahashi S, Yamamoto T, Tsutsumi Z, Moriwaki Y, Yamakita J, Higashino K. Close correlation between visceral fat accumulation and uric acid metabolism in healthy men. Metabolism. 1997; 46:1162–1165.